Stock AnalizVera Therapeutics, Inc. VERA
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Vera Therapeutics, Inc. (VERA) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $10M and net income of -$415M, a net margin of -4041.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -42%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $10M | — | — | — | — | — | — |
| Net income | -$415M | -$300M | -$152M | -$96M | -$89M | -$33M | -$53M |
| Free cash flow | -$376M | -$242M | -$136M | -$92M | -$68M | -$24M | -$35M |
| EPS (diluted) | $-5.90 | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 | $-166.93 |
| Net margin | -4041.2% | — | — | — | — | — | — |
| ROIC | — | -36.5% | -20.9% | -51.9% | -66.4% | -32.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $71.36, 154% above the current price; targets range from $29.00 to $100.00; the consensus rating is “Strong buy”; expected EPS is $-5.95 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Vera Therapeutics pay a dividend?
Not currently.
Is Vera Therapeutics a good stock to buy?
We do not give buy or sell advice. Vera Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.